The EU MedTech Innovation Pressure: Navigating 2026 "Crunch" and EY-DG SANTE Findings For years, the European Union was the global launchpad for EU MedTech Innovation, but recent data suggests a pivotal identity crisis is looming. A "CE Mark" was often the first major milestone for a startup before tackling the FDA. However, the tide has turned. As we move deeper into the mid-2020s, the medical technology landscape is facing a pivotal identity crisis. The recent EY-DG SANTE study , commissioned by the European Commission, has provided the data to back up what many MedTech professionals have been whispering in boardrooms: the regulatory burden of the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) is creating an "innovation drain." The Data Speaks: Key Findings from the EY-DG SANTE Study The study was designed to monitor the availability of medical devices on the EU market. The results are a wake-up call. According to the ...
The 74% Tipping Point: Why Indian Pharma is Going "All-In" on AI If you picked up the newspaper this week, you might have seen a striking statistic that should make every pharmaceutical executive sit up and take notice. A recent report highlights that 74% of Indian business leaders now rank Artificial Intelligence (AI) as their top technology adoption choice for 2025. This isn’t just a "tech trend." It is a massive divergence from the global average, where only about 55% of leaders prioritize AI with the same intensity. For those of us in the pharmaceutical and medical device sectors, this number confirms what we've been seeing on the ground: India is no longer just the "Pharmacy of the World"—it is rapidly becoming the "AI Lab of the World." Key Insight: As we move through 2025, the conversation has shifted from "Will AI replace us?" to "How can AI agents execute complex workflows for us?" Let...